IMG_3371.png
Plz interpret this
Reading File
analyse_media
Finding Sources
Searching PubMed
"invasive ductal carcinoma" AND "no special type" AND "grade 3" AND prognosis
Finding Sources
Reading File
Finding Sources
Here is a complete, plain-language interpretation of this histopathology report.
Histopathology Report Interpretation
Patient & Sample Details
| Field | Details |
|---|---|
| Patient | Mrs. P Shreelatha, 28 years / Female |
| Referring Doctor | Dr. Suneetha K, MBBS DNB(OBG) |
| Clinical History | Atypical lesion in the left breast, classified as BIRADS IV-A on imaging |
| Specimen | Multiple grey-white core biopsy pieces, 0.8 - 1.5 cm |
| Reported | 11-Aug-2026 |
What BIRADS IV-A Means
BIRADS (Breast Imaging-Reporting and Data System) IV-A is the category assigned on imaging (ultrasound/mammogram) that means a "low suspicion" finding that nonetheless warrants biopsy. That is why this core biopsy was done -- to get a definitive tissue answer.
Microscopic Findings - Plain Language Breakdown
The pathologist examined the biopsy cores under a microscope and found the following:
| Finding | What It Means |
|---|---|
| Tumor tissue in lobules separated by fibrous septa | Cancer cells are growing in clusters divided by fibrous bands of tissue |
| Large areas of necrosis | Significant patches of dead cancer cells - a feature of rapidly growing, high-grade tumors that outpace their own blood supply |
| Diffuse sheets and collapsed tubules | Cancer cells are growing chaotically in flat sheets rather than forming normal breast structures (tubules), which is a hallmark of poorly differentiated cancer |
| Moderate anisonucleosis | The nuclei of cancer cells vary significantly in size and shape - a sign of abnormality |
| Vesicular chromatin | The nucleus has a pale, open texture (vesicular), indicating high transcriptional activity -- a feature of aggressive cells |
| Brisk mitosis | Cancer cells are dividing rapidly and frequently, confirming high-grade behavior |
| Plenty of lymphocytic infiltration | The body's immune cells (lymphocytes) have flooded the area. This is actually a potentially positive sign -- called Tumour-Infiltrating Lymphocytes (TILs), and higher TIL levels are associated with better response to chemotherapy in high-grade breast cancers |
The Diagnosis: IDC-NST, High Grade
IDC-NST = Invasive Ductal Carcinoma - No Special Type
This is the most common form of breast cancer (about 70-80% of all cases).
- Invasive - the cancer cells have broken out of the milk duct walls and are growing into the surrounding breast tissue. This does NOT mean it has spread to other organs yet - that requires staging.
- Ductal - it originated in the milk ducts of the breast.
- No Special Type (NST) - previously called "Not Otherwise Specified (NOS)." It means the tumor does not fit into a specific rarer pattern (like mucinous, tubular, or lobular). NST is simply the standard, most common category.
- High Grade (Grade 3) - cancer cells look very different from normal breast cells and are dividing fast. Grade 3 tumors tend to grow more quickly and are more likely to respond to chemotherapy (as compared to low-grade tumors).
In 28-year-old women, breast cancers tend to be biologically more aggressive and are more often high-grade. This is consistent with the findings here. - Robbins & Kumar Basic Pathology; Washington Manual of Medical Therapeutics
The Critical Next Step: IHC Advised
The pathologist has specifically recommended IHC (Immunohistochemistry). This is the single most important next test before any treatment decision is made.
IHC will determine the biological subtype of the cancer by testing for three receptors:
| Marker | What It Tests | Why It Matters |
|---|---|---|
| ER (Estrogen Receptor) | Does the cancer grow in response to estrogen? | ER+ tumors are treated with hormone-blocking therapy (e.g., tamoxifen) |
| PR (Progesterone Receptor) | Does it grow in response to progesterone? | Confirms hormone sensitivity |
| HER2 (Human Epidermal growth factor Receptor 2) | Is the HER2 gene amplified/overexpressed? | HER2+ tumors respond to targeted drugs like trastuzumab (Herceptin) |
The combination of these three results will classify the cancer into one of four subtypes:
- Luminal A (ER+/PR+, HER2-, low Ki67) - best prognosis, hormone therapy
- Luminal B (ER+/PR+, HER2+ or high Ki67) - moderate prognosis
- HER2-enriched (ER-, PR-, HER2+) - targeted therapy
- Triple Negative (ER-, PR-, HER2-) - most aggressive subtype, requires chemotherapy
Summary in Simple Terms
This biopsy confirms breast cancer - specifically a high-grade invasive ductal carcinoma of the left breast. The cancer is aggressive in appearance (rapidly dividing cells, areas of dead tissue, highly abnormal nuclei). The immune system has responded with significant lymphocyte infiltration, which is actually a favorable sign for treatment response. The next mandatory step is IHC testing to identify the receptor status, which will determine the treatment plan (surgery, chemotherapy, hormone therapy, and/or targeted therapy).
What Should Happen Next
- IHC report - ER, PR, HER2 (and ideally Ki67 for proliferation index)
- Complete staging - CT scan of chest/abdomen/pelvis, bone scan (to check for spread)
- Referral to a multidisciplinary breast cancer team - oncologist, breast surgeon, radiation oncologist
- Genetic counseling - at only 28 years of age, BRCA1/BRCA2 mutation testing is strongly advised
⚠️ Important: This interpretation is for educational purposes only. Please discuss these results directly with the treating oncologist, who will plan the full workup and treatment. Do not make any medical decisions based on this explanation alone.
This is a shared conversation. Sign in to Orris to start your own chat.